Literature DB >> 34564793

A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020.

Takehiko Wada1, Takuji Ishimoto2,3, Izaya Nakaya4, Takehiko Kawaguchi5, Tadashi Sofue6, Sayaka Shimizu7, Noriaki Kurita8, Sho Sasaki9, Hiroki Nishiwaki10, Masahiro Koizumi1, Shoji Saito2, Nobuhiro Nishibori2, Yuji Oe11, Mai Yoshida11, Yoshitaka Miyaoka12, Shin'ichi Akiyama2, Yuya Itano2, Masaki Okazaki2, Takaya Ozeki2, Daisuke Ichikawa13, Hideyo Oguchi14, Satoshi Kohsaka15, Shiho Kosaka16, Yuki Kataoka17, Hideaki Shima18, Sayuri Shirai13, Kazuhiro Sugiyama19, Tomo Suzuki20, Daisuke Son21, Tomomi Tanaka22, Eishu Nango23, Kakuya Niihata8, Yoko Nishijima24, Kandai Nozu25, Midori Hasegawa26, Rei Miyata27, Masahiko Yazawa13, Yoshihiro Yamamoto28, Ryohei Yamamoto29, Yugo Shibagaki13, Kengo Furuichi30, Hirokazu Okada31, Ichiei Narita32.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34564793     DOI： 10.1007/s10157-021-02098-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  4 in total

1.  Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.

Authors:  Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Asami Takeda; Tatsuo Tsukamoto; Shunya Uchida; Kazuhiko Tsuruya; Tatsuya Shoji; Hiroki Hayashi; Yasuhiro Akai; Megumu Fukunaga; Tsuneo Konta; Saori Nishio; Shunsuke Goto; Hirofumi Tamai; Kojiro Nagai; Ritsuko Katafuchi; Kosuke Masutani; Takashi Wada; Tomoya Nishino; Arimasa Shirasaki; Hiroshi Sobajima; Kosaku Nitta; Kunihiro Yamagata; Junichiro J Kazama; Keiju Hiromura; Hideo Yasuda; Makoto Mizutani; Toshiyuki Akahori; Tomohiko Naruse; Takeyuki Hiramatsu; Kunio Morozumi; Tetsushi Mimura; Yosuke Saka; Eiji Ishimura; Hajime Hasegawa; Daisuke Ichikawa; Takashi Shigematsu; Hiroshi Sato; Ichiei Narita; Yoshitaka Isaka
Journal:  J Nephrol       Date:  2022-04-02       Impact factor: 3.902

2.  Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.

Authors:  Yang He; Weijin Fang; Zuojun Li; Chunjiang Wang
Journal:  Invest New Drugs       Date:  2022-07-22       Impact factor: 3.651

3.  Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study.

Authors:  Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Asami Takeda; Shunya Uchida; Tatsuo Tsukamoto; Kazuhiko Tsuruya; Yasuhiro Akai; Kosaku Nitta; Megumu Fukunaga; Hiroki Hayashi; Kosuke Masutani; Takashi Wada; Tsuneo Konta; Ritsuko Katafuchi; Saori Nishio; Shunsuke Goto; Hirofumi Tamai; Arimasa Shirasaki; Tatsuya Shoji; Kojiro Nagai; Tomoya Nishino; Kunihiro Yamagata; Junichiro J Kazama; Keiju Hiromura; Hideo Yasuda; Makoto Mizutani; Tomohiko Naruse; Takeyuki Hiramatsu; Kunio Morozumi; Hiroshi Sobajima; Yosuke Saka; Eiji Ishimura; Daisuke Ichikawa; Takashi Shigematsu; Tadashi Sofue; Shouichi Fujimoto; Takafumi Ito; Hiroshi Sato; Ichiei Narita; Yoshitaka Isaka
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

4.  Effectiveness and Safety of Rehabilitation for Pediatric Patients with Nephrotic Syndrome in the Acute Phase: A Case Study.

Authors:  Aki Tabata; Hiroki Yabe; Yuya Mitake; Tomohiro Shirai; Marina Yoshida; Rie Kurosu; Ken Kawamura
Journal:  Prog Rehabil Med       Date:  2022-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.